Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

Genders eligible for Study: Both Age: between 18 and 55 years Healthy volunteers are accepted Inclusion Criteria: Subjects tested positive for HIV-1 infection (HIV-infected subjects). Subjects that are tested negative for HIV (Healthy subjects). Either on stable antiretroviral therapy or not on antiretroviral therapy. CD4 cells > = 200 - 750/µl. Subjects must be in good general health except for HIV infection. Women must not be pregnant and use an acceptable method of contraception. Exclusion Criteria: Impairment of immunologic function (other than HIV infection). History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure. Uncontrolled serious infection. History of or active autoimmune disease. History or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders. History of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before the age of 50 years. High risk of developing a myocardial infarction or coronary death. History of intravenous drug abuse (within the last 12 months). Known allergy to egg or aminoglycoside (gentamicin). History of anaphylaxis or severe allergic reaction. Subjects undergoing treatment for tuberculosis infection or disease. Chronic administration of systemic immuno-suppressants.